Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Cost-effectiveness analysis of different dipeptidyl-peptidase 4 inhibitor drugs for treatment of type 2 diabetes mellitus

Full text
Author(s):
Cazarim, Maurilio de Souza [1] ; Coelho da Cruz-Cazarim, Estael Luzia [1] ; Baldoni, Andre de Oliveira [2] ; Enes dos Santos, Thais Bueno [2] ; de Souza, Paula Goncalves [2] ; Silva, Ingrid de Almeida [2] ; Reis Rodrigues, Roberta Niriam [2] ; Franco Correa Maia, Alda Cristina [2] ; Leira Pereira, Leonardo Regis [1] ; Sanches, Cristina [2]
Total Authors: 10
Affiliation:
[1] Univ Sao Paulo, Fac Pharmaceut Sci Ribeirao Preto, Sao Paulo - Brazil
[2] Fed Univ Sao Joao del Rei UFSJ, Sao Joao Del Rei, MG - Brazil
Total Affiliations: 2
Document type: Journal article
Source: DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS; v. 11, n. 2, SI, p. S859-S865, DEC 2017.
Web of Science Citations: 2
Abstract

Introduction: Type 2 diabetes mellitus (T2DM) has burdened health systems in the world to the value of 500 billion dollars/year. Dipeptidyl peptidase 4 inhibitors (DPP-4 Inhibitors) have been strongly associated with spending on the treatment of T2DM by the courts in Brazil. The aim of this study was to estimate the most cost-effective DPP-4 Inhibitor for T2DM treatment. A pharmacoeconomic study of cost-effectiveness was performed in a medium-sized municipality in Minas Gerais state, Brazil. Methods: The data are from legalization in municipal health in 2013. The effectiveness of DPP-4 Inhibitors was measured by the reduction in glycated hemoglobin (A1c). The direct medical costs of drug and adverse drug reactions were identified. With these data, a cost-effectiveness ratio (CER) and construction of the decision tree for sensitivity analysis were performed. Results: The representative of the most effective in reducing A1c gliptins was sitagliptin in combination with metformin, it was able to reduce A1c by 1.16% (1.09 to 1.22, CI 95%). The drug with the lowest cost was linagliptin, with a cost per patient/year of US\$ 481.42. Sensitivity analysis performed by the decision tree shows that sitagliptin in association with metformin had the CER of US\$ 1,506.75 per patient/year, to reduce A1c by 1%. Conclusion: The most cost-effective DPP-4 Inhibitor was sitagliptin with metformin. (C) 2017 Diabetes India. Published by Elsevier Ltd. All rights reserved. (AU)

FAPESP's process: 14/02087-9 - Long-term economic evaluation of pharmaceutical care for patients with systemic arterial hypertension
Grantee:Maurilio de Souza Cazarim
Support type: Scholarships in Brazil - Master